This technology is useful for delivery of therapeutic agents to specific cell targets to treat disease.
Many therapeutic agents in clinical development suffer from poor toxicity profiles. Thus, targeted delivery of therapeutic agents to avoid systemic toxicity has been an ongoing pursuit of interest. Attempts have been made towards targeted delivery by combining therapeutic agents with targeting agents, such as antibodies. Antibody-drug-conjugates (ADCs) have had some success but tend to be limited by the drug loading capacity and poor bio-distribution. This technology of antibody drug nanocarriers improves upon the drug loading capacity by 100-fold while also preserving the natural pharmacokinetics of antibodies.
This technology employs drug nanocarriers made up of metal nanoparticles (NPs) that are less than 10nm in diameter. The metal NPs have amphiphilic organic outer shells that are capable of adsorbing large amounts of hydrophobic therapeutic agents (50 or more per nanoparticle). Therapeutic agents such as peptides or proteins can also be covalently linked to the NPs. The NPs are attached to the antibodies through bioconjugation at the hinge region so as to not disrupt the natural pharmacokinetics or bio-distribution of the antibody. Upon targeting to specific cells, the antibody drug nanocarriers are endocytosed, and the therapeutic agents are released into the cytosol.
- Larger therapeutic agent loading capacity for targeting agents compared to existing technologies
- Small nanocarriers conjugation preserves natural pharmacokinetics and bio-distribution of the targeting agents